Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

NCT00630032 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

762

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: cyclophosphamide
DRUG: Docetaxel
DRUG: epirubicin hydrochloride
DRUG: fluorouracil
DRUG: ixabepilone

Sponsor

UNICANCER